Several things patients must know when taking the drug: What are the warnings and precautions for trametinib?

In clinical studies of Trametinib, new primary malignancies , bleeding, colitis and gastrointestinal perforation, venous thromboembolic events, cardiomyopathy, ocular toxicity, Interstitial lung disease/pneumonia, severe febrile reactions, skin reactions, hyperglycemia, hemophagocytic lymphohistiocytosis, embryo-fetal toxicity and other warnings and precautions. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. New primary malignant tumors: During treatment with the combination of trametinib and dabrafenib, 2% of patients developed cutaneous squamous cell carcinomas (cuSCCs) and keratoacanthoma. Basal cell carcinoma and new primary melanoma occur in 3% and <1% of patients, respectively. Prior to initiating trametinib, perform dermatologic evaluation every 2 months during treatment and for up to 6 months after discontinuation of combination therapy. Monitor patients receiving trametinib and dafinib closely for signs or symptoms of noncutaneous malignancies. No dose adjustment of trametinib is required in patients who develop noncutaneous malignancies.

2. Bleeding: Including major bleeding defined as symptomatic bleeding in critical areas or organs, which may occur with MEKINIST. Deaths have been reported. Serious bleeding events, including gastrointestinal bleeding, intracerebral bleeding, uterine bleeding, postoperative bleeding, and epistaxis. Permanently discontinue trametinib for all Grade 4 bleeding events and for any Grade 3 bleeding event that does not improve.

3. Colitis and gastrointestinal perforation: Trametinib monotherapy and dabrafenib administration (adults): In the combined safety population, colitis occurred in <1% of patients and gastrointestinal perforation occurred in <1% of patients. Monitor patients closely for colitis and gastrointestinal perforation.

4. Venous thromboembolic events: may include deep vein thrombosis (DVT) and pulmonary embolism (PE). If the patient develops symptoms of DVT or PE, such as shortness of breath, chest pain, or swelling of the arms or legs, it is recommended to seek medical attention immediately. For life-threatening PE, permanently discontinue trametinib. For uncomplicated DVT and PE, withhold trametinib for up to 3 weeks.

5. Cardiomyopathy: Including heart failure, which may occur, that is, the left ventricular ejection fraction (LVEF) decreases by ≥10% from baseline and is below the institutional lower limit of normal (LLN). Assess LVEF by echocardiography or multiple acquisition (MUGA) scan before initiating single-dose trametinib or combination therapy, one month after starting treatment, and then every every 2 to 3 months during treatment. Discontinue for asymptomatic absolute decline of LVEF of 10% or more from baseline and below LLNTrametinib up to 4 weeks.

6. Eye toxicity: including retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), etc. Urgent (within 24 hours) ophthalmological evaluation of patient-reported vision loss or other visual impairment. Permanently discontinue trametinib in patients with documented RVO. Perform ophthalmic evaluations regularly and any time the patient reports visual disturbances. If RPED is diagnosed, discontinue use of trametinib.

7. Interstitial Lung Disease (ILD)/Pneumonia: Trametinib should be discontinued pending clinical investigation in patients who develop new or progressive pulmonary symptoms and findings, including cough, dyspnea, hypoxia, pleural effusion, or infiltrates. Permanently discontinue trametinib in patients diagnosed with treatment-related ILD or pneumonitis.

8. Severe febrile reaction: Severe febrile reaction and fever of any severity may occur, accompanied by hypotension, chills or chills, dehydration or renal failure. If the patient's body temperature≥38°C, discontinue Megenix during monotherapy and use trametinib and dabrafenib in combination. In case of recurrence, treatment can also be interrupted at the first symptom of fever. If the patient has had a previous severe febrile reaction or febrile episode associated with a complication, administer a fever-reducing medication as secondary prevention when resuming trametinib. Give corticosteroids (eg, 10 mg of prednisone daily) for at least 5 days.

9. Skin reactions: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and drug reactions with eosinophilia and systemic symptoms (DRESS), have been reported during treatment, which may be life-threatening or fatal. Monitor for new or worsening serious skin reactions.

10. Hyperglycemia: For patients with existing diabetes or hyperglycemia, monitor their blood sugar levels when starting medication and when clinically appropriate. Initiate or optimize antihyperglycemic medications as clinically indicated.

11. Hemophagocytic lymphohistiocytosis (HLH): If HLH is suspected, interrupt treatment. If HLH is confirmed, discontinue treatment and initiate appropriate management of HLH.

12. Embryonic-Fetotoxicity: Based on the results of animal studies and its mechanism of action, taking trametinib to pregnant women can cause harm to the fetus. Trametinib has embryotoxic and abortive effects in rabbits at doses greater than or equal to the resulting exposure that is approximately 0.3 times the human exposure at the recommended adult clinical dose. Inform pregnant women of potential risks to the fetus. It is recommended that female patients of childbearing potential use effective contraception during treatment with Megenix and for 4 months after treatment.